Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Clin Cancer Res. 2018 Jan 4;24(7):1654–1666. doi: 10.1158/1078-0432.CCR-17-2168

Figure 4. Preclinical repurposing of chemotherapies.

Figure 4

A, Repurposing screen of 114 FDA approved and/or clinical trial drugs. Heatmap (left) reports 72 hour IC50 against the indicated cell type; grey bars (middle) indicate FDA approved drugs; graph (right) reports number of completed trials of each drug. Arrows denote drugs selected for further study in (B). B, ‘Washout studies’: heatmaps report IC50 values after timed exposures of the indicated cell types to drug. C–D, (top) bioluminescence measurement of tumor growth. In parenthesis are the days (d) when treated tumor volume was significantly (p<0.05, non-parametric) less than control. (Bottom) survival curves of mice with indicated tumor types treated with the indicated drug monotherapy. Comparisons between treatments are Log Rank not significant (ns) and P<0.0005(***).